Simulations Plus, Inc. (SLP)
| Market Cap | 1.10B |
| Revenue (ttm) | 45.69M |
| Net Income (ttm) | 10.81M |
| Shares Out | 20.11M |
| EPS (ttm) | 0.54 |
| PE Ratio | 101.22 |
| Forward PE | 119.05 |
| Dividend | $0.24 |
| Dividend Yield | 0.44% |
| Trading Day | June 22 |
| Last Price | $54.66 |
| Previous Close | $54.80 |
| Change ($) | -0.14 |
| Change (%) | -0.26% |
| Day's Open | 54.64 |
| Day's Range | 54.06 - 55.10 |
| Day's Volume | 48,407 |
| 52-Week Range | 49.34 - 90.84 |
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will participate in Craig-Hallum's 18th Annual Institutional Investor Conference on June 2, 2021.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will participate in the 16th Annual Needham Virtual Technology & Media Conference on Thursday, May 20, 2021.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus (SLP) announced today that its securities will be listed on The Nasdaq Global Select Market with the open of business on May 13, 2021
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases ADMET Predictor APX.2, its flagship machine learning platform with new & enhanced capabilities in discovery PBPK simulations
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that the US FDA renewed its licensing to the DILIsym Services division's flagship QST software platform, DILIsym.
Simulations Plus' (SLP) fiscal second-quarter results benefit from strong performance of the company's higher-margin software business.
Simulations Plus (SLP) delivered earnings and revenue surprises of 7.14% and 1.68%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Simulations Plus (NASDAQ:SLP) moved higher after the company reported Q2 results. Quarterly Results Earnings per share increased 25.00% over the past year to $0.15, which beat the estimate of ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported record 2nd quarter results for FY2021. Net revenue of $13.1 million, up 27% over 2QFY20; YTD revenue of $23.8 million.
On Monday, April 12, Simulations Plus (NASDAQ:SLP) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Simulations Plus (SLP) fiscal second-quarter results are likely to reflect gains from solid uptick in modeling and simulations workflow platform for drug development across pharma and biotech industries.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports excellent results from its Artificial Intelligence-driven Drug Design (AIDD) module in ADMET Predictor in testing by partner.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its 2nd quarter fiscal year 2021 results on Monday, April 12, 2021, with a webcast at 4:15 pm ET.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the formation of a Scientific Advisory Board to guide the development of its RENAsym QST kidney injury software platform.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the successful launch of its 2021 MIDD+ Scientific Conference with speakers from industry, academia, & regulatory agencies.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will present at Oppenheimer's 31st Annual Healthcare Conference on March 16, 2021, beginning at 2:30 p.m. ET.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that its DILIsym division and the University of Pittsburgh Drug Discovery Institute jointly received a Phase I SBIR grant.
What's better than rapid growth and a dividend payment?
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host fireside chat at BTIG's Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 18, at 12pm ET.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the release of GastroPlus 9.8.1 with key enhancements to improve efficiency and inform regulatory decision making.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced an agreement to distribute Lixoft's MonolixSuite in China with Mosim, one of China's leading clinical CROs.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it is partnering with the Institute of Pharmaceutical Sciences (ICF) in Brazil, to expand into South America.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it has awarded a grant to Uganda's Makerere University funding upgraded infrastructure to facilitate research.
Simulations Plus (SLP) fiscal first-quarter results reflect solid software and service revenue growth. However, coronavirus crisis affected renewals.
The company continues to anticipate swift, double-digit revenue growth over the next several quarters.
New York, New York--(Newsfile Corp. - January 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of Simulations Plus, Inc. (NASDAQ: SLP) concerning possible breaches of fiduciary ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that CEO Shawn O'Connor will present at the 23rd Annual Needham Virtual Growth Conference on January 14, 2021, at 2pm ET.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced a new funded collaboration with a large pharmaceutical partner to enhance PBPK/PD models for pulmonary therapeutics.
Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q1 2021 Results - Earnings Call Transcript
Simulations Plus (SLP) delivered earnings and revenue surprises of 9.09% and 1.35%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Simulations Plus (NASDAQ:SLP) were flat after the company reported Q1 results. Quarterly Results Earnings per share increased 9.09% year over year to $0.12, which beat the estimate of $0.11.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported record 1st quarter results for FY2021. Net revenues of $10.7 million increased 14%; net income was up 21% over 1QFY20.
Simulations Plus (NASDAQ:SLP) releases its next round of earnings this Monday, January 11. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.
Simulations Plus (SLP) fiscal first-quarter results are likely to reflect gains from solid uptick in modeling and simulations workflow platform for drug development across pharma and biotech industries.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced a new funded collaboration to enhance its GastroPlus ACAT model with novel mechanisms for oral peptide formulations.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its first quarter fiscal year 2021 results on Monday, Jan. 11, 2021, with a webcast at 4:15 pm ET
We discuss three software stocks -- COUP, NUAN and SLP -- which might not sustain market beating run in 2021, owing to persistent macroeconomic weakness across SMBs induced by coronavirus outbreak.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it has published its inaugural Environmental, Social and Governance (ESG) report on its website's Investors page
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the appointment of Will Frederick as CFO, succeeding John Kneisel who is retiring after 7 years with the Company.
Simulations Plus (SLP) fiscal fourth-quarter results reflect solid software and service revenue growth. However, coronavirus crisis affected renewals.
Simulations Plus' (SLP) CEO Shawn O'Connor on Q4 2020 Results - Earnings Call Transcript
Simulations Plus (SLP) delivered earnings and revenue surprises of 20.00% and 0.85%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Simulations Plus (NASDAQ:SLP) fell 2.16% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to $0.11, w...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported results for the 4th quarter and fiscal year 2020. Full FY20 revenues increased 22.4%; 4QFY20 revenues increased 18.9%.
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2020 Earnings Release and Conference Call
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its 4th quarter and fiscal year 2020 results on Mon., Nov. 16, 2020, with a webcast at 4:15 pm ET
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that CEO Shawn O'Connor will be participating in the Credit Suisse Virtual Healthcare Conference on Nov. 10, 2020.
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ORCL vs. SLP: Which Stock Is the Better Value Option?
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the release of GastroPlus 9.8 with key improvements to non-oral delivery models, virtual bioequivalence, and DDIs.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that its Board of Directors has declared a cash dividend of $0.06 per share to be distributed on Nov. 2, 2020.
About SLP
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides ... [Read more...]
| Industry Health Information Services | IPO Date Jun 18, 1997 |
| Stock Exchange NASDAQ | Ticker Symbol SLP |
Financial Performance
In 2020, SLP's revenue was $41.59 million, an increase of 22.43% compared to the previous year's $33.97 million. Earnings were $9.33 million, an increase of 8.72%.
Analyst Forecasts
According to 4 analysts, the average rating for SLP stock is "Buy." The 12-month stock price forecast is 84.67, which is an increase of 54.90% from the latest price.